Physician profile
Elbridge Bills
NPI 1043270135
$1,232.89
in general payments reported to CMS, 2019-2025
27 companies · $26.19 in 2025
The $26.19 reported for 2025 was less than what a typical Gynecology provider received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $210 · 2020: $196 · 2021: $343 · 2022: $147 · 2023: $195 · 2024: $116 · 2025: $26.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $336.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $309.63 | 2019-2023 | Lo Loestrin Fe |
| Astellas Pharma US INC | $112.16 | 2022-2024 | Veozah |
| Dysis Medical, INC. | $93.02 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $79.19 | 2020-2023 | |
| Avion Pharmaceuticals | $75.08 | 2021-2023 | Balcoltra |
| Organon LLC | $61.44 | 2021-2024 | Nexplanon |
| Novo Nordisk INC | $58.23 | 2020-2023 | Wegovy |
| Aspira Women'S Health INC | $45.57 | 2021 | |
| Millicent US INC | $43.58 | 2020-2024 | Intrarosa |
| Ascend Therapeutics US, LLC | $36.78 | 2023 | |
| Exeltis, USA INC. | $32.60 | 2019 | |
| Lupin INC. | $27.20 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $26.19 | 2025 | Myfembree |
| Medtronic, INC. | $24.34 | 2021 | |
| Agile Therapeutics, INC. | $23.65 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $21.59 | 2023 | Mara Console |
| Mylan Pharmaceuticals INC. | $20.60 | 2021 | |
| Pfizer INC. | $20.42 | 2021 | |
| Lilly USA, LLC | $19.50 | 2024 | Zepbound |
| Covidien LP | $16.40 | 2019 | |
| Vertical Pharmaceuticals, LLC | $16.37 | 2019 | |
| Avanos Medical | $14.89 | 2019 | |
| Roche Diagnostics Corporation | $14.69 | 2019 | |
| Mayne Pharma Commercial LLC | $14.34 | 2021 | |
| Allergan, INC. | $13.30 | 2019 | |
| Axonics, INC. | $12.13 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elbridge Bills listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.